Dr. Greenbaum is the Chair of Type 1 Diabetes TrialNet, an NIH-sponsored international consortium to test disease-modifying therapies in T1D. She'll be joining the CWD team to talk about the latest developments in TrialNet research, as well as answering any questions from our community. Hear first-hand from Dr. Greenbaum how these discoveries relate to people living with T1D and how their family members have an opportunity to contribute to research dedicated to the prevention of type 1 diabetes.
This video was originally broadcasted live via webinar on January 17, 2021 at 7 pm ET.
Carla Greenbaum, MD, is Director of the Diabetes Program at Benaroya Research Institute (BRI) in Seattle, a non-profit research center focused on translational and clinical studies of type 1 diabetes (T1D) and other immune-mediated diseases. She also serves as Chair of Type 1 Diabetes TrialNet, an NIH-sponsored international consortium to test disease-modifying therapies in T1D. She received her medical degree at Brown University and completed her endocrinology fellowship at the University of Washington. Dr. Greenbaum is a clinical investigator who works to alter the course of T1D through understanding the causes of disease, and testing interventions to alter immune-mediated beta cell dysfunction. Her expertise includes clinical trial design and implementation as well as discovery and evaluation of biomarkers for disease course and response to therapy.